128 related articles for article (PubMed ID: 22856408)
1. [Pituitary atypical adenoma or malignant corticotrophinoma?].
Alves M; Paiva I; Belo F; Rebelo O; Bastos M; Carvalheiro M
Acta Med Port; 2011 Dec; 24 Suppl 3():661-6. PubMed ID: 22856408
[TBL] [Abstract][Full Text] [Related]
2. Atypical type II silent corticotrophic adenoma developing into Cushing's disease upon second recurrence.
Psaras T; Honegger J; Buslei R; Saeger W; Klein D; Capper D; Meyermann R; Mittelbronn M
Exp Clin Endocrinol Diabetes; 2007 Oct; 115(9):610-5. PubMed ID: 17943697
[TBL] [Abstract][Full Text] [Related]
3. Biochemical behaviour of an incidentally diagnosed silent corticotroph adenoma.
Benaiges D; Puig J; Lafuente J; Gimeno J; Prados M; Sagarra E; Flores-Le-Roux J
Neuro Endocrinol Lett; 2012; 33(3):290-3. PubMed ID: 22635086
[TBL] [Abstract][Full Text] [Related]
4. ACTH- and prolactin-producing pituitary gland microadenoma with biphasic features of atypia and intermediate filament expression.
Mittelbronn M; Psaras T; Capper D; Meyermann R; Honegger J
Neuro Endocrinol Lett; 2006; 27(1-2):89-92. PubMed ID: 16648816
[TBL] [Abstract][Full Text] [Related]
5. "Silent"corticotropinoma.
Pawlikowski M; Kunert-Radek J; Radek M
Neuro Endocrinol Lett; 2008 Jun; 29(3):347-50. PubMed ID: 18580839
[TBL] [Abstract][Full Text] [Related]
6. Low aryl hydrocarbon receptor-interacting protein expression is a better marker of invasiveness in somatotropinomas than Ki-67 and p53.
Kasuki Jomori de Pinho L; Vieira Neto L; Armondi Wildemberg LE; Gasparetto EL; Marcondes J; de Almeida Nunes B; Takiya CM; Gadelha MR
Neuroendocrinology; 2011; 94(1):39-48. PubMed ID: 21178332
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathologic correlations of silent corticotroph adenomas of the pituitary: report of four cases and literature review.
Sahli R; Christ ER; Seiler R; Kappeler A; Vajtai I
Pathol Res Pract; 2006; 202(6):457-64. PubMed ID: 16497445
[TBL] [Abstract][Full Text] [Related]
8. P53 gene mutation in an atypical corticotroph adenoma with Cushing's disease.
Kawashima ST; Usui T; Sano T; Iogawa H; Hagiwara H; Tamanaha T; Tagami T; Naruse M; Hojo M; Takahashi JA; Shimatsu A
Clin Endocrinol (Oxf); 2009 Apr; 70(4):656-7. PubMed ID: 18771563
[No Abstract] [Full Text] [Related]
9. Early recognition of aggressive pituitary adenomas: a single-centre experience.
Ceccato F; Regazzo D; Barbot M; Denaro L; Emanuelli E; Borsetto D; Rolma G; Alessio L; Gardiman MP; Lombardi G; Albiger N; D'Avella D; Scaroni C
Acta Neurochir (Wien); 2018 Jan; 160(1):49-55. PubMed ID: 29170844
[TBL] [Abstract][Full Text] [Related]
10. [Immunohistochemistry for pituitary hormones and Ki-67 in growth hormone producing pituitary adenomas].
Brito J; Sáez L; Lemp M; Liberman C; Michelsen H; Araya AV
Rev Med Chil; 2008 Jul; 136(7):831-6. PubMed ID: 18949157
[TBL] [Abstract][Full Text] [Related]
11. ACTH-secreting Crooke cell carcinoma of the pituitary.
Kovács GL; Góth M; Rotondo F; Scheithauer BW; Carlsen E; Saadia A; Hubina E; Kovács L; Szabolcs I; Nagy P; Czirják S; Hanzély Z; Kovács K; Horváth É; Korbonits M
Eur J Clin Invest; 2013 Jan; 43(1):20-6. PubMed ID: 23134557
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathologic correlates of giant pituitary adenomas.
Chacko G; Chacko AG; Lombardero M; Mani S; Seshadri MS; Kovacs K; Scheithauer BW
J Clin Neurosci; 2009 May; 16(5):660-5. PubMed ID: 19285407
[TBL] [Abstract][Full Text] [Related]
13. Multiregional sampling reveals a homogenous distribution of Ki-67 proliferation rate in pituitary adenomas.
Wolfsberger S; Kitz K; Wunderer J; Czech T; Boecher-Schwarz HG; Hainfellner JA; Knosp E
Acta Neurochir (Wien); 2004 Dec; 146(12):1323-7; discussion 1327-8. PubMed ID: 15480830
[TBL] [Abstract][Full Text] [Related]
14. [Pituitary carcinoma. Anatomic and clinical features of cases reported in literature].
Sidibé EH
Neurochirurgie; 2007 Aug; 53(4):284-8. PubMed ID: 17524431
[TBL] [Abstract][Full Text] [Related]
15. PTTG and Ki-67 expression in pituitary adenomas.
Wierzbicka-Tutka I; Sokołowski G; Bałdys-Waligórska A; Adamek D; Radwańska E; Gołkowski F
Przegl Lek; 2016; 73(2):53-8. PubMed ID: 27197423
[TBL] [Abstract][Full Text] [Related]
16. Determination of Ki-67 labeling index in pituitary adenomas using MIB-1 monoclonal antibody.
Lath R; Chacko G; Chandy MJ
Neurol India; 2001 Jun; 49(2):144-7. PubMed ID: 11447433
[TBL] [Abstract][Full Text] [Related]
17. Survivin products in pituitary tumors.
Jankowska A; Wasko R; Waligorska-Stachura J; Andrusiewicz M; Jaskula M; Liebert W; Sowinski J
Neuro Endocrinol Lett; 2008 Dec; 29(6):1033-7. PubMed ID: 19112393
[TBL] [Abstract][Full Text] [Related]
18. Pituitary macroadenomas (>3 cm) in young adulthood: Pathologic and proliferative characteristics.
Öngürü Ö; Düz B; Şimşek H; Günal A; Gönül E
Neurol Neurochir Pol; 2015; 49(4):212-6. PubMed ID: 26188936
[TBL] [Abstract][Full Text] [Related]
19. Adrenocorticotropic hormone-producing pituitary carcinoma with intracranial metastases.
Shastri BR; Nanda A; Fowler M; Levine SN
World Neurosurg; 2013 Feb; 79(2):404.e11-6. PubMed ID: 22079280
[TBL] [Abstract][Full Text] [Related]
20. Adrenocorticotropic hormone secreting pituitary adenomas: analysis of growth fraction using the MIB-1 antibody.
Mastronardi L; Guiducci A; Spera C; Puzzilli F; Liberati F; Ruggeri A; Peciarolo A
Tumori; 2000; 86(3):229-32. PubMed ID: 10939604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
